CPI Patient Safety & Risk Management 3 — Questions and Answers
Question 1: A clinical trial site receives an urgent safety communication from the sponsor indicating that a new risk of liver toxicity has been identified. What is the investigator's IMMEDIATE obligation?
- Discontinue all enrolled participants from the study
- Review the communication, notify the IRB, and assess currently enrolled participants per sponsor guidance (Correct answer)
- Wait for FDA confirmation before taking any action
- Inform participants only at their next scheduled visit
Correct answer: Review the communication, notify the IRB, and assess currently enrolled participants per sponsor guidance
The investigator must promptly review new safety information, report it to the IRB, and implement any required monitoring or protocol changes to protect participants.
Question 2: In clinical research, which of the following BEST describes the 'blame-free' culture essential to patient safety?
- Staff are never held accountable for errors regardless of intent
- Errors are reported without fear of punishment so systemic problems can be identified and fixed (Correct answer)
- Only supervisors review error reports to prevent staff anxiety
- Near-misses are excluded from reporting to reduce administrative burden
Correct answer: Errors are reported without fear of punishment so systemic problems can be identified and fixed
A blame-free culture encourages transparent reporting by ensuring that individuals can report errors without fear of punitive consequences, enabling system improvement.
Question 3: A pediatric clinical trial participant's parent reports that the child accidentally ingested a double dose of the investigational product. How should this be classified?
- A protocol deviation only
- A potential adverse event requiring immediate clinical assessment and documentation (Correct answer)
- A minor incident requiring only a note in the participant's file
- An expected event that does not require reporting
Correct answer: A potential adverse event requiring immediate clinical assessment and documentation
Overdose of an investigational product is an adverse event requiring clinical evaluation, documentation, and notification to the sponsor.
Question 4: Which failure mode is MOST commonly identified in clinical trials through a Failure Mode and Effects Analysis (FMEA)?
- Sponsor budget overruns
- Process steps that could lead to participant harm if they fail (Correct answer)
- Investigator fee payment delays
- Insufficient randomization block sizes
Correct answer: Process steps that could lead to participant harm if they fail
FMEA proactively identifies process steps where failure could harm participants, allowing risk mitigation before the trial begins.
Question 5: A clinical investigator notices that several participants are not properly completing the study diary, leading to incomplete safety data. What is the BEST course of action?
- Exclude non-compliant participants from the analysis
- Re-train participants on diary completion and document the retraining (Correct answer)
- Fabricate plausible entries to complete the record
- Transfer the participants to a different arm of the study
Correct answer: Re-train participants on diary completion and document the retraining
Retraining and documenting the effort ensures data integrity while maintaining participant safety monitoring through complete records.
Question 6: Under 21 CFR Part 312, which of the following adverse events requires expedited 15-day reporting by the sponsor to the FDA?
- Any adverse event listed in the investigator's brochure
- Unexpected serious adverse events that are reasonably related to the investigational drug (Correct answer)
- All grade 1 or grade 2 adverse events
- Protocol deviations that do not affect participant safety
Correct answer: Unexpected serious adverse events that are reasonably related to the investigational drug
Unexpected serious adverse drug reactions that may be causally related to the investigational product require expedited 15-day reporting to FDA under 21 CFR 312.32.
Question 7: A site coordinator discovers that a participant was enrolled despite not meeting a key inclusion criterion. What type of issue is this, and who must be notified?
- A minor deviation; only the PI needs to know
- A protocol deviation; the IRB and sponsor must be notified per site SOPs (Correct answer)
- A fraud matter; immediately notify law enforcement
- An administrative oversight; correct the file and proceed
Correct answer: A protocol deviation; the IRB and sponsor must be notified per site SOPs
Enrollment of an ineligible participant is a protocol deviation that may affect participant safety and data integrity, requiring IRB and sponsor notification.
CPI Patient Safety & Risk Management 3
A clinical trial site receives an urgent safety communication from the sponsor indicating that a new risk of liver toxicity has been identified.
What is the investigator's IMMEDIATE obligation?